EW · 10-Q · 2026Q3 · Full report

End-Market Demand Trends

Edwards Lifesciences Corp · 2026-11-04 · Importance 70 · Surprise 56

For the first nine months of 2026, TAVR net sales increased 11.1% year over year, primarily on higher sales of the Edwards SAPIEN platform, particularly SAPIEN 3 Ultra RESILIA. TMTT sales rose 47.7%, driven by PASCAL TEER, EVOQUE tricuspid valve replacement, and SAPIEN M3 mitral valve replacement in the United States and Europe. Surgical sales increased 6.3%, with higher sales of INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA in the United States and Europe.

Key facts

• Edwards Lifesciences is assessing potential effects of increased U.S. import tariffs and non-U.S. retaliatory tariffs and may mitigate them through its supply chain or potential exemptions and exclusions; insufficient mitigation could reduce product demand and adversely affect its business, financial condition, and results. source
• Edwards Lifesciences’ R&D expense increased in the three and nine months ended September 30, 2026, primarily due to greater investment in aortic transcatheter valve and mechanical circulatory support system technology. source
• For the nine months ended September 30, 2026, Edwards Lifesciences’ R&D expense increase also included investments in implantable heart failure management and advanced technology innovation. source